These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 20433955)
1. Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis. Papagoras C; Voulgari PV; Drosos AA Autoimmun Rev; 2010 Jun; 9(8):574-82. PubMed ID: 20433955 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany. Beresniak A; Baerwald C; Zeidler H; Krüger K; Neubauer AS; Dupont D; Merkesdal S Clin Exp Rheumatol; 2013; 31(3):400-8. PubMed ID: 23464803 [TBL] [Abstract][Full Text] [Related]
3. [Management for TNF failure]. Mukai M Nihon Rinsho; 2007 Jul; 65(7):1299-307. PubMed ID: 17642247 [TBL] [Abstract][Full Text] [Related]
4. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. Gibbons LJ; Hyrich KL BioDrugs; 2009; 23(2):111-24. PubMed ID: 19489652 [TBL] [Abstract][Full Text] [Related]
5. [The meaning of biologic therapy in the treatment of rheumatoid arthritis with the focus on clinical remission. Part II. Tocilizumab, Abatacept, Rituximab--drugs characterised by a different mechanism of action than TNF-alpha inhibitors]. Swierkot J; Madej M Pol Merkur Lekarski; 2011 Apr; 30(178):289-94. PubMed ID: 21595177 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists. Isaacs JD Expert Opin Biol Ther; 2009 Dec; 9(12):1463-75. PubMed ID: 19916731 [TBL] [Abstract][Full Text] [Related]
7. [Non-TNF biologicals in the therapeutic strategy for rheumatoid arthritis]. Wollenhaupt J; Krüger K Z Rheumatol; 2010 Sep; 69(7):618-25. PubMed ID: 20703488 [TBL] [Abstract][Full Text] [Related]
8. Biological therapy for rheumatoid arthritis: where are we now? Horton SC; Emery P Br J Hosp Med (Lond); 2012 Jan; 73(1):12-8. PubMed ID: 22241404 [TBL] [Abstract][Full Text] [Related]
9. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C; Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098 [TBL] [Abstract][Full Text] [Related]
10. [Biologicals in the treatment of rheumatic diseases]. Scherer HU; Burmester GR Dtsch Med Wochenschr; 2006 Oct; 131(41):2279-85. PubMed ID: 17036270 [No Abstract] [Full Text] [Related]
12. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Rubbert-Roth A; Finckh A Arthritis Res Ther; 2009; 11 Suppl 1(Suppl 1):S1. PubMed ID: 19368701 [TBL] [Abstract][Full Text] [Related]
13. Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage. Prescrire Int; 2009 Oct; 18(103):198-201. PubMed ID: 19882783 [TBL] [Abstract][Full Text] [Related]
14. Targeted therapy in rheumatoid arthritis. Köller MD Wien Med Wochenschr; 2006 Jan; 156(1-2):53-60. PubMed ID: 16465614 [TBL] [Abstract][Full Text] [Related]
15. Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade. Manadan AM; Block JA Am J Ther; 2008; 15(1):53-8. PubMed ID: 18223354 [TBL] [Abstract][Full Text] [Related]
16. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Salliot C; Finckh A; Katchamart W; Lu Y; Sun Y; Bombardier C; Keystone E Ann Rheum Dis; 2011 Feb; 70(2):266-71. PubMed ID: 21097801 [TBL] [Abstract][Full Text] [Related]
17. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ; Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186 [TBL] [Abstract][Full Text] [Related]
18. [A novel treatment option in rheumatoid arthritis: abatacept, a selective modulator of T-cell co-stimulation]. Dejaco C; Duftner C; Wipfler E; Schirmer M Wien Med Wochenschr; 2009; 159(3-4):70-5. PubMed ID: 19247593 [TBL] [Abstract][Full Text] [Related]
19. Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis. Johnston SS; Turpcu A; Shi N; Fowler R; Chu BC; Alexander K Semin Arthritis Rheum; 2013 Aug; 43(1):39-47. PubMed ID: 23453683 [TBL] [Abstract][Full Text] [Related]
20. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries. Cantini F; Niccoli L; Goletti D J Rheumatol Suppl; 2014 May; 91():56-64. PubMed ID: 24789001 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]